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Although locoregional relapse is frequent after definitive radiotherapy (RT) or multimodal treatments, re-irradiation
is only performed in few patients even in palliative settings like e.g. vertebral metastasis. This is most due to
concern about potentially severe complications, especially when large volumes are exposed to re-irradiation. With
technological advancements in treatment planning the interest in re-irradiation as a local treatment approach has
been reinforced. Recently, several studies reported re-irradiation for spinal metastases using SBRT with promising
local and symptom control rates and simultaneously low rates of toxicity. These early data consistently indicate that
SBRT is a safe and effective treatment modality in this clinical situation, where other treatment alternatives are rare.
Similarly, good results have been shown for SBRT in the re-irradiation of head and neck tumors. Despite severe late
adverse effects were reported in several studies, especially after single fraction doses >10 Gy, they appear less
frequently compared to conventional radiotherapy. Few studies with small patient numbers have been published
on SBRT re-irradiation for non-small cell lung cancer (NSCLC). Overall survival (OS) is limited by systemic progression
and seems to depend particularly on patient selection. SBRT re-irradiation after primary SBRT should not be
practiced in centrally located tumors due to high risk of severe toxicity. Only limited data is available for SBRT
re-irradiation of pelvic tumors: feasibility and acceptable toxicity has been described, suggesting SBRT as a
complementary treatment modality for local symptom control.
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Despite technological and biological advances in malig-
nant disease management, loco-regional failure remains a
frequent challenge after primary radio-(chemo)therapy as
recent studies have shown for different entities [1-5]. The
locoregional failure rate is 41.7% at three years after con-
comitant radiochemotherapy for locally advanced head
and neck squamous-cell carcinoma (HNSCC) [2]. Locore-
gional recurrences are reported in up to 85% of the
patients after radiochemotherapy for locally advanced
non-small cell lung cancer (NSCLC) [6,7]. The locoregio-
nal recurrence rate in women treated with radioche-
motherapy for cervical cancer was 35% in a met-analysis
of 13 trials over all stages (Ia – IVa) [8].
The intention of treatment for locoregional recur-
rences is manifold and depends on factors like disease* Correspondence: Mantel_F@klinik.uni-wuerzburg.de
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reproduction in any medium, provided the ortype, extent of initial disease and recurrence, metastatic
status, primary treatment, interval to locoregional recur-
rence, performance status, age of the patients and symp-
toms of the recurrent disease. Consequently, the goal of
re-treatment ranges between palliative symptom control,
prevention of symptoms due to progressive disease and
curative treatment in the absence of metastatic spread.
Locoregional recurrences are a major challenge because
therapeutic options are limited in many tumor sites after
both primary surgical and radiotherapy treatment. The
overall frequency of re-irradiation for locoregional recur-
rences is unknown. Even in a palliative setting of spinal
metastases, re-irradiation is practiced in few patients only
[9]. One important reason might be the fear or risk of nor-
mal tissue toxicity in the re-irradiation situation.Normal tissue tolerance in the re-irradiation situation
Whereas useful guidelines do exist for normal tissue toler-
ance in the primary situation [10] information in the re-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tematic clinical analyses have been performed. Animal
models have been used for many decades to evaluate nor-
mal tissue tolerance in the re-irradiation situation. While
providing the opportunities of systematic study protocols,
the transfer of the results from such animal studies into
clinical practice must be performed with caution [11]: The
simulation of previous oncological and non-oncological
therapies or co-morbidities is not possible in animal stud-
ies. Due to multimodal therapies many patients e.g. re-
ceive chemotherapy before, during or after radiotherapy
or are referred to a surgical resection. Combination of dif-
ferent treatment modalities can lead to increased toxicity.
Also long-term follow-up is difficult in animal models.
Less severe or more subtle toxicity cannot be evaluated in
animal studies but might be of clinical relevance. Uniform
dose distributions, which are most frequently used in ani-
mal studies, are not representative for modern intensity-
modulated radiation therapy (IMRT) / SBRT. Lastly, small
sample numbers lead to wide confidence intervals espe-
cially at the low-risk part of the normal tissue complica-
tion probability (NTCP) curve.
Regarding re-irradiation tolerance of acute responding
tissue, clinical studies have shown an almost complete re-
covery within a few months. After full dose re-irradiation
in 169 patients with unresectable head and neck cancer,
De Crevoisier et al. showed that the incidence of grade 3
mucositis and dermatitis was not significantly different
during the first and the second radiotherapy course [12].
In a hyper-fractionated re-irradiation series of 13 patients
with recurrent or metastatic abdominal malignancies,
only one patient developed grade 3 acute toxicity (ab-
dominal pain and gastro-intestinal bleeding) requiring
hospitalization [13].
With regard to re-irradiation of late responding tis-
sue, tolerance is depending on the specific organ at risk.
For epithelial and mesenchymal tissues, animal studies
suggest almost complete recovery of dermal structures
[14]. However clinical data show increased rates of se-
vere toxicity and some studies have shown a dose and
volume effect [15,16]. No valid normal tissue complica-
tion probability model (NTCP) has been found. Another
late-responding tissue complication is osteonecrosis. No
clear dose and volume effect has been reported. In an ana-
lysis of 115 reirradiated head and neck cancer patients,
Salama et al. reported a 11% osteoradionecrosis rate of
the mandible after a median lifetime radiation dose of 135
Gy [17]; patients in this study had been treated with a
three-dimensional conformal radiation therapy (3D-CRT).
Later studies using IMRT showed that sparing of the man-
dible seems to reduce the rate of osteonecrosis [18,19].
Concerning lung toxicity, good recovery was found in
animal models for the acute pneumonitis phase. Recovery
took place in 1–3 months and was best for treatmentdoses less than 75% of the tolerance dose [20]. In contrast,
recovery is smaller for late pulmonary fibrosis. For clinical
practice this implicates, that re-irradiation in the pulmon-
ary region should be practiced primarily in palliative situa-
tions with short life expectancy unless sparing of the lungs
is possible. No recovery has been observed in animal stud-
ies for the heart, bladder or kidney nor are there any sys-
tematic clinical analyses available. Sparing of these organs
seems to be of importance.
With respect to spinal cord tolerance in the re-irradiation
situation, again animal models have been used for syste-
matic examination of spinal cord damage and recovery.
Ang et al. reported a re-irradiation series to the spinal cord
in 56 rhesus monkeys: only 4 of 45 animals developed
myeloparesis after a first course of 44 Gy followed by re-
irradiation course with 57.2 Gy after 1 and 2 years or with
66 Gy after 2 and 3 years, respectively. Recovery of the
spinal cord was modelled in two ways: an optimistic model
described spinal cord recovery by 76%, 85% and 101% of
the initial 44 Gy dose after 1, 2 and 3 years. A pessimistic
model described the overall recovery equivalent by 61%
[21]. The spinal cord tolerance after re-irradiation with a
single fraction radiosurgery was examined in 23 female
Yucatan minipigs by Medin et al. [22]. After a uniform dose
of 30 Gy in 10 fractions to the spinal cord, the minipigs
were re-irradiated with single-fraction radiosurgery and the
dose was positioned laterally to the spinal cord resulting in
an inhomogeneous dose distribution to the spinal
cord (effective dose 50 (ED50) of 19.7 Gy). Identical spinal
cord tolerance for radiosurgery was observed whether or
not a prior conventionally fractionated radiotherapy had
been performed, which indicates full recovery of 30 Gy
after 1 year.
Clinical data support the hypothesis of relevant spinal
recovery. Analysing the clinical data of 40 patients
retreated with conventional fractionation published in 8
different series, Nieder et al. came to the conclusion that
the risk of myelopathy is low if cumulative doses to the
spinal cord do not exceed 70-75 Gy (2 Gy-fractionated
equivalent dose, α/β = 2 (EQD2/2)), single course doses
do not exceed 50 Gy (EQD 2/2) and the interval be-
tween the two courses is not shorter than 6 months
[23]. In case of re-irradiation to the spinal cord with
hypo-fractionated stereotactic body radiotherapy, Sahgal
et al. performed a case–control study and reported simi-
lar results to Nieder et al. [24]: the risk of RM seems to
be low if the initial course does not exceed 50 Gy (EQD
2/2), the SBRT-course does not exceed 25 Gy (EQD 2/2)
and the interval between the two courses is not shorter
than 5 months.
Rational for using SBRT in the re-irradiation situation
To limit normal tissue toxicity in the reirradiation situ-
ation, the target volume is confined to the recurrent
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elective nodal irradiation or coverage of larger areas of
potential microscopic spread: imaging technologies like
FDG-PET are helpful in differentiation of recurrent
tumor and post-surgical or radiation induced fibrosis.
Highly conformal treatment planning by the use of
IMRT or volumetric-modulated arc therapy (VMAT)
reduces incidental exposure of normal tissue especially
to high irradiation doses; however, a larger low-dose vol-
ume needs to be considered. To further reduce irradi-
ation of normal tissue, tight safety margins around the
recurrent tumor are vital and can today be realized by
the use of daily image-guidance. Effective immobilization
of the patient or active motion management strategies
need to be applied to minimize intra-fractional uncer-
tainties. Adaptive re-planning might be required in the
situation of clinically relevant tumor regression or other
anatomical changes during the treatment course.
In this context, stereotactic body radiotherapy needs to
be interpreted as a combination of all above-described
technologies aiming at best possible accuracy of the whole
radiotherapy workflow. Also the short treatment time due
to hypo-fractionated delivery of SBRT is to be considered
as re-treatment often takes place in a palliative intention.
SBRT re-irradiation for spinal metastases
Radiotherapy is an essential treatment modality in the
management of symptomatic vertebral metastases either
for pain palliation, the prevention or control of neuro-
logical symptoms or pathological fractures. By using
conventionally fractionated radiation protocols with low
irradiation doses of 8 – 40Gy in 1 – 20 fractions, good
pain response has been reported in the literature [25-27].
However, the achieved duration of pain control is short
with a median of 3–6 months [9]. As overall survival has
improved substantially in many cancer sites due to
modern systemic approaches, re-treatment with conven-
tionally fractionated RT has been used and achieves pain
control in approximately 60% of the patients [28] but is
performed in only few patients due to the fear of radiation
induced myelopathy.
Therefore, several studies investigating SBRT for spinal
metastases in preirradiated areas have been performed
in the last decade summarized in Table 1 [29-37]. All
studies used either IMRT, a robotic stereotactic radiosur-
gery system or tomotherapy for highly conformal dose
distributions and daily image-guidance was performed in
all studies. However, substantial variability in the reirra-
diation doses, fractionation and assumed spinal cord re-
covery is seen in the literature. The median total dose
(TD) of the first radiation course ranged from 30–39.2
Gy and the interval between the first course and the
SBRT-retreatment ranged between 11–25 months. Me-
dian TD for re-irradiation was 30 Gy in most of thetrials given in approximately 5 fractions (median 3–22).
The accumulated spinal cord dose ranged between 48–
83.4 Gy EQD2, indicating no consensus about spinal
cord recovery.
Overall, a very low incidence of myelopathy was
observed. In the study conducted by Choi et al. one pa-
tient of 42 (incidence 2%) developed a grade 4 spinal
cord neurotoxicity. This patient had received a spinal
cord total dose of 40 Gy for metastatic breast cancer in
the first course and a stereotactic radiation surgery for a
10.5 cm3 T5 recurrence with 20 Gy in 2 fractions. Dose
was prescribed to the 80% isodose line. The maximal
spinal cord dose in the SBRT course was 19.25 Gy [30].
Garg et al. observed 2 of 59 patients (incidence 3.3%)
with grade 3 neurological toxicity related to nerve dam-
age without loss of independent ambulatory function
[32]. Mahadevan et al. described 4 patients of 60 (6.7%)
with persistent or even worsening neurological symp-
toms, yet all of them having corresponding radiological
progression [33]. There were no cases of myelopathy in
the other studies.
Local control (LC) ranged from 63% to 100% and
therefore seems to be very promising (details see
Table 1). Damast et al. analysed the largest study popula-
tion: 97 tumor sites were retreated with image-guided
IMRT, resulting in a local control rate of 66% at one
year. Patients in this study were either re-irradiated with
5 × 4 Gy or 5 × 6 Gy. The comparison between the two
dose groups showed a significant difference in cumula-
tive local failure after one year: 26% for the 30 Gy group
and 45% for the 20 Gy group [31]. Milker-Zabel et al.
reported a local control rate of 94.7% after a median
follow-up of 12.3 months in 18 patients (19 lesions) re-
treated with either fractionated stereotactic conformal
RT or IMRT [35]. No local recurrences at the time of
follow-up were observed in the analyses by Mahan et al.,
but only eight patients were re-treated in this study of
whom one died of distant disease briefly after treatment
and one 11 months after treatment [34]. Mahadevan
et al. reported SBRT for patients with progressive epi-
dural disease: at a median follow-up time of 12 months
they observed a 93% rate of stable or improved epidural
disease, results equally to surgery in this situation [33].
Some studies examined pain control as an endpoint:
Damast et al. reported a significant, mild or no pain re-
lief in 46%, 31% and 23% of the patients, respectively
[31]. Pain relief occurred in 13 of 16 patients (81%) in
the analysis of Milker-Zabel et al. [35]. Sterzing et al.
reported a reduction of tumor-related pain on a visual
analogue scale (0 – 10, 0 = no pain; 10 – worst imagin-
able pain) from a median value of 7 down to a median
value of 3 after 6 weeks (p = 0.0046) [37].
In conclusion, these findings suggest that SBRT is a
safe and effective treatment modality in the re-treatment
Table 1 SBRT reirradiation for spinal metastases
Clinical trial No. patients/
treatments
Dose 1st
RT course
(median)
Interval
(median months)
Reirradiation TD/
fraction number
(median)
Accumulated dose
to spinal cord EQD2
(median)
Planning Set-up/imaging Follow-up
(months)
Myelopathy Local/pain
control
Milker-Zabel
et al. 2003
18/19 38Gy 17.7 39.6Gy n/s ss-IMRT Stereotactic 12.3 0% 94.7%
Mahan et al.
2005
8/8 30Gy n/s 30Gy/15 48Gy Tomotherapy Daily MV-CT 15.2 0% 100% at
time of fu
Sahgal et al.
2009
25/37 36Gy 11 24Gy/3 n/s Cyberknife kV tracking 7 0% 70%
Choi 2010 42/51 40Gy 19 20Gy/2 76Gy Cyberknife kV tracking 7 n=1 G4 73%
Sterzing et al.
2010
36/36 36.3Gy 17.5 34.8Gy/11 46.5Gy Tomotherapy Daily MV-CT 7.5 0% 1-year 76%
2-years 63%
Damast et al.
2010
95/97 30Gy n/s 20-30Gy/5 54.3Gy IMRT Daily portal
images or CBCT
12.1 0% 1-year 66%
Garg et al.
2011
59/63 30Gy n/s 27-30Gy/3-5 n/s IMRT Daily CT on rails
or CBCT
13 n=2 G3 peripheral
nerve injury
76%
Mahadevan
et al. 2011
60/81 30Gy 20 24-30Gy/3-5 n/s Cyberknife kV tracking 12 n=3 persistent
radicular pain
93%
n=1 lower-extremity
weakness
Chang et al.
2012
49/54 39.2Gy 25 27Gy/3 83.4Gy Cyberknife kV tracking 17.3 0% 79%
Abbreviations: RT = radiotherapy; TD = total dose; n/s = not specified; ss-IMRT = single shot intensity-modulated radiation therapy; MV-CT = megavolt computed tomography; kV = kilo Volt; CBCT = cone beam
computed tomography; IMRT = intensity modulated radiation therapy; G = grade.
M
antelet
al.Radiation
O
ncology
2013,8:7
Page
4
of
13
http://w
w
w
.ro-journal.com
/content/8/1/7
Mantel et al. Radiation Oncology 2013, 8:7 Page 5 of 13
http://www.ro-journal.com/content/8/1/7situation when conventional radiotherapy is unable to be
within spinal dose tolerance. However, further know-
ledge about spinal recovery and spinal cord tolerance to
inhomogeneous SBRT dose distributions is required.SBRT re-irradiation for lung tumors (NSCLC)
In locally advanced lung cancer, locoregional recurrence
remains high in up to 85% of patients [6,7]. Intrathoracic
relapse in previously irradiated areas of patients is a fre-
quent challenge in clinical routine. However, re-
irradiation of NSCLC is performed in only 1.5% to 8.1%
of all patients [7,38,39].
In 2011 Jeremic et al. reviewed 11 studies (two of
them prospective) of conventionally fractionated ex-
ternal beam radiation therapy (EBRT) re-irradiation
for recurrent NSCLC. The analyses showed an improved
overall survival (OS) after retreatment with higher
doses compared to low-dose retreatments accompa-
nied by increased rates of grade 2–3 pneumonitis and
esophagitis [40]. The rational for SBRT therefore is
safely escalating the irradiation dose while minimising
toxicity (Table 2).Table 2 SBRT reirradiation for lung cancer
Clinical trial Poltinnikov et al.
No. patients/treatment 17/17
Dose 1st RT course ≥ 50 Gy
Interval (median) n/s
Total re-irradiation dose median 32Gy (17.5 – 42.0)
Single fraction dose median 4Gy (2.5 – 4.2)
Technology SBF
Target size median field size 95cm2
(30–189)
Symptom relief 11/13
Median follow-up (range) n/s
Local control 5/17 responders
Median Overall survival (range) 5.5 months (2.5–30)
Toxicity G2 esophagitis n=4
G2 pneumonits n=1
Abbreviations: RT = radiotherapy; n/s = not specified; SBF = stereotactic body frame
FDG-PET = fluorodeoxyglucose positron emission tomography; G = grade; @ = at tiPoltinnikov et al. examined the outcome and dosimet-
ric predictors of acute esophagitis in 17 NSCLC patients
receiving re-irradiation using a stereotactic body frame
(SBF) [41]. Hypofractionated 3-dimensional RT was used
with a median RT dose of 32 Gy (range, 4 – 42 Gy) and
a median fraction size of 4 Gy (2.5 – 4.2 Gy). Multiple
noncoplanar RT fields (median 6) were used in each pa-
tient to minimize spinal cord exposure. In this study re-
irradiation was defined as treatment of areas that had
received a full RT of 50 Gy or more 13 patients had
symptoms as pain or shortness of breath. After re-treat-
ment, 11 of these 13 symptomatic patients had improved
or even complete disappearance of symptoms. Grade 1
and 2 acute esophagitis was observed in 7 patients, how-
ever symptoms disappeared within 3 months after RT.
One patient suffered from pneumonitis grade 2. Notably,
no grade 3 toxicities and no bronchial or vascular toxici-
ties were observed. Radiologic response rates before
death or at the time of last follow-up showed one patient
with complete response, 4 patients with partial response
and 5 patients with stable disease whereas 7 patients had
disease progression. Median overall survival time was
5.5 months (2.5 – 30 months).Coon et al. Kelly et al.
12/12 36/36
n/s median 61.5 Gy
(range, 30–79.2 Gy)
n/s 22.0 months (range, 0–92 months)
60Gy 50 Gy (72%)
40 Gy (17%)
Other (11%)
20Gy 12.5 Gy (72%)
10Gy (17%)
Other (11%)
Cyberknife SBF, 4D-CT, FDG-PET
median GTV 14.3cc Tumor size (median) 1.7cm
(range, 0.6–3.8 cm)
n/s n/s
12 months 15 months (4–45)
92% @ 1a 92%
67% @ 1a 59% @ 2a
No G3 toxicity At least one G3 in 33% of patients
G3 peunomitis n=7
G3 esophagitis n=3
G3 Skin ulcer n=2
G3 Cough n=1
No G4/5 toxicities
; 4D-CT = 4-dimensional computed tomography;
me of; a = year.
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Cyberknife Radiosurgery Robotic System Coon et al.
evaluated the role of positron-emission tomography in
the planning and evaluation of RT treatment response.
Among these patients 12 patients with recurrent disease
after definitive treatment were described [42]. Re-
treatment doses in these patients were three fractions of
20 Gy whereas no information was given about the ini-
tial radiation doses or treatment intervals. Treating
volumes were substantially smaller compared to the
study of Poltinnikov et al. with a median gross tumor
volume of 14.3 cm3 compared to a median field size of
95 cm2, respectively. Local control rates and overall sur-
vival rates one year after reirradiation were 92% and 67%,
respectively. Similar to the study mentioned above no
G3 toxicities occurred.
Kelly et al. retrospectively reviewed the medical
records of 36 patients treated with SBRT for relapse of
NSCLC who had been previously irradiated to the chest
[43]. In-field relapse was defined as a recurrence in an
area that had received an initial dose of more than 30
Gy in the first EBRT course. The median tumor size was
1.7 cm for SBRT re-irradiation and most of the patients
received 50 Gy in 4 fractions. The median initial EBRT
dose was 62 Gy and the median interval between EBRT
and SBRT 22 months. The median follow-up time after
SBRT was 15 months in this study. The overall 2-year
survival was 59% and 2-year progression-free survival
was 26%: the most frequent site of failure was intrathor-
acic. However, only 13.6% (3 patients of 22) of these
intrathoracic relapses occurred inside the SBRT field and
the authors mention that planning target volume (PTV)
dose coverage and/or total dose and fractionation was
suboptimal in two of the three patients. At least one
form of late grade 3 toxicity was observed in 12 patients
(33%). Grade 3 pneumonitis was experienced by 7
patients and with 11 patients suffering from grade 2
pneumonitis the latter was the most frequent toxicity in
this analysis. Three patients developed grade 3 esopha-
gitis, two grade 3 chest wall ulcers, and two patients
developed grade 3 cough. Overall no grade 4 or 5 tox-
icity occurred.
In conclusion, few studies with small patient numbers
are available about SBRT for re-irradiation of NSCLC.
Definition of re-irradiation differs among the studies as
well as total doses and fractionation schemes. Overall
survival seems to depend particularly on patient selec-
tion and is limited by systemic progression. All investi-
gations do show promising local control rates that seem
to exceed RT with conventional techniques. Furthermore
small field SBRT for re-irradiation to the chest seems to
be safe.
SBRT for reirradiation after prior SBRT has been eval-
uated in a retrospective analysis of 32 patients by Peulenet al. [44]. 29 patients received two SBRT courses, two
received three and one patient even four SBRT courses.
Re-irradiation was defined as an overlap of more than 50%
of the PTV. The median interval between the two SBRT
courses was 14 months and the median follow-up time
from the beginning of re-irradiation 12 months, respec-
tively. Most patients (n = 23) were treated for pulmonary
metastases. The results showed eight patients with grade
3–4 toxicity and three patients suffered from grade 5
toxicity and died of massive haemorrhage. All patients
with grade 4–5 toxicity were treated for centrally
located tumors. Additionally, larger clinical target volumes
(CTV) were associated with severe toxicity and poorer
local control. LC 5 months after re-treatment was 52%
with actuarial 1-year and 2-year survival rates of 59% and
43%, respectively.
Consequently, a second course of SBRT with overlap-
ping target volumes should only be considered in cases
of small recurrent tumors and peripheral location.
SBRT re-irradiation for head & neck cancer
Therapy options for locoregional recurrences in previ-
ously irradiated head and neck patients are limited. Sal-
vage surgery is the standard treatment for small relapses
[45,46]. But with further locoregional spread, surgery
alone is not sufficient. In the past patients considered in-
operable often received palliative chemotherapy with low
response rates ranging from 10% to 40% [47,48]. Salama
et al. reported the long-term outcome of concurrent treat-
ment with chemotherapy and re-irradiation of patients
suffering from recurrent or second primary squamous cell
carcinoma of the head and neck (SCCHN) [17]. Full-dose
re-irradiation in this multimodal therapy setting showed
promising results for long-term survival. 115 patients had
been treated with conventional RT techniques for the ini-
tial and the second course. Locoregional control and free-
dom from distant metastasis rate at three years was 51%
and 61%, respectively. Re-treatment was highly toxic with
19 treatment related toxic events, five of them due to ca-
rotid haemorrhages. The authors came to the conclusion
that re-irradiation of recurrent head and neck cancer
should be limited to clinical trials.
As normal tissue toxicity was significant after conven-
tional RT, the introduction of SBRT in the re-irradiation
of head and neck cancer patients has been pursued in
the last years. Several approaches for SBRT have been
published recently.
Voynov et al. reviewed 22 patients re-treated with
SBRT in recurrent previously irradiated SCCHN [49].
Using the Cyberknife patients were irradiated with a me-
dian single fraction dose of 5 Gy for a median of 5 frac-
tions (details see Table 3). Re-treatment with SBRT was
considered to be safe as no grade 4 or 5 toxicities or late
toxicities occurred. In 2009 Roh et al. published an
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cancer re-irradiated with Cyberknife radiosurgery (RS)
with three fractions of 10 or 13 Gy (34 sites of 44). The
authors changed to a fractionation schedule of five frac-
tions of 5 Gy or 8 Gy [50]. 15 patients (42.9%) showed
complete tumor regression and 13 (37.1%) partial regres-
sion with median local control rates and overall survival
rates after one year of 61% and 52.1%, respectively. Late
adverse events were observed in three patients: two
grade 4 and one grade 5 toxicity: one patient suffered
from mandible bone necrosis five months after RS; the
treated submandibular tumor mass abutted the mandible
in that case. Two patients developed a chronic mucosal
ulcer, trismus and skull-base necrosis 4–6 months after
treatment. All of these patients had received a full dose
radiation of 66 to 70.2 Gy in the first RT-course and a
RS dose of 30 to 39 Gy in 3 fractions. The authors men-
tioned that these RS doses might be too high: 30 to 39
Gy in 3 fractions are equivalent to 80-130 Gy in conven-
tionally 2 Gy-fractionated radiotherapy based on an α/β
of 3 Gy. After adapting the dose and fractionation proto-
col to 25–40 Gy in 5 fractions (biologically equivalent
dose 40–90 Gy2) no late complications have been
observed so far. Besides dose and fractionation the in-
ter-/intratreatment mucosal movement due to swallow-
ing and respiration was mentioned as a risk for chronic
mucosal ulceration.
Unger et al. reported on stereotactic RS reirradiation in
65 head and neck cancer patients [51]. Treatment sites
were oropharynx (n = 13), hypopharynx (n = 8), naso-
pharynx (n = 7), paranasal sinus (n = 7), neck (n = 7), and
others (n = 23). Patients were treated with SBRT reirra-
diation definitively (n = 38) or in palliative intention due
to metastatic or untreated local disease (n = 27). Nine
patients had complete macroscopic resection before SBRT
and 33 patients were treated with simultaneous chemora-
diotherapy. Initial RT dose was median 67 Gy (32–120
Gy) and median treatment interval between initial course
and SBRT 26 months. Most patients were treated with
5 x 6 Gy (2–5 × 4–12Gy) but dose and fractionation was
individualized by the treating physician and total dose
was commonly reduced after complete macroscopic re-
section. For 56 patients evaluable for response,
complete, partial and no response was observed in 30
patients (54%), 15 patients (27%) and 11 patients
(20%), respectively. Median overall survival was 12
months. The OS rate was 41% for definitively treated
patients and the locoregional control rate 30% in these
patients. The authors reported that nasopharynx site,
surgical resection and higher total dose were signifi-
cantly correlated with improved locoregional control
and nonsquamous histology and surgical resection with
improved OS. One patient died of unspecified causes 2
weeks after reirradiation, considered treatment related.Grade 4 late toxicities were observed in six patients
(9%) including soft tissue necrosis, arterial bleeding, fistula
formation and severe dysphagia. No association of higher
RS dose or higher cumulative dose with severe late com-
plications was seen, though quantitative analysis were lim-
ited due to the small number of events.
Heron et al. conducted a phase I dose escalation trial
of re-irradiation with SBRT for recurrent SCCHN in
2009 [52]. 25 SCCHN patients were reirradiated either
with 5 × 5 Gy (n = 3), 5 × 6.4 Gy (n = 3), 5 × 7.2 Gy
(n = 3), 5 × 8 Gy (n = 6) or 5 × 8.8 Gy (n = 10). The
authors observed treatment response in 76% of the patients.
However, they could not correlate dose and tumor size
to the probability of local control. The authors could not
find an association between dose and toxicity due to the
small number of adverse events. The highest dose applied
(44 Gy) was considered to be adequate for a phase II trial.
To increase efficacy of SBRT reirradiation, later on Heron
et al. investigated combinations of SBRT with cetuximab
[53]. Therefore they compared two patient groups in a
retrospective-matched cohort study: 35 patients were
treated with SBRT reirradiation alone or with additional
weekly cetuximab during SBRT, respectively. Toxicities
were comparable in both patient cohorts and an overall
survival benefit was seen for the cetuximab arm. Feasibil-
ity and efficacy of SBRT reirradiation with or without
cetuximab also was shown recently by Comet et al. [54].
In a retrospective analysis of 51 patients re-irradiated
for locally recurrent nasopharyngeal carcinoma (LRNPC)
Ozyigit et al. compared 24 patients treated with SBRT to
27 patients treated with 3D-CRT [55]. Median total dose
in the first treatment course was 67.4 Gy (range, 59.4–
70 Gy) for the 3D-CRT group and 70 Gy (range, 48–70
Gy) for the SBRT group (p = 0.1). Median total reirradia-
tion dose was 57 Gy with a single fraction dose of 2 Gy
per day using 3D-CRT. Patients in the SBRT arm were
retreated with a total dose of 30 Gy delivered over 5
consecutive days. There was no significant difference in
the 2-year actuarial local control rate (82% and 80% for
the SBRT and 3D-CRT group, respectively, p=0.6) and
the 2-year actuarial cancer-specific survival (64% and
47% for the SBRT and 3D-CRT group, respectively,
p=0.4). In contrast the authors observed a significant dif-
ference in the rate of late side effects. Serious late toxici-
ties occurred in 21% of the patients treated with SBRT
compared to 48% of the patients treated with 3D-CRT.
The follow-up was similar for SBRT and 3D-CRT with
median 23 months and 24 months, respectively, and pa-
tient characteristics were comparable as well. Taken into
account that serious late toxicities after reirradiation of
LRNPC had been reported before to be as high as 15-45%
[56-59] SBRT therefore seems to be an attractive
treatment modality with less late side effects and shorter
treatment times for the re-irradiation of LRNPC.
Table 3 SBRT reirradiation for head and neck cancer
Clinical trial Voynov et al. 2006 Heron et al. 2009 Unger et al. 2010 Roh et al. 2009 Ozyigit et al. 2009 Vargo et al. 2012
n 22 25 65 36 24 34
Initial therapy dose median BED10 97.8 Gy
(70.1 – 190.3 Gy)
median, 64.7 Gy median 67 Gy
(32–120 Gy)
median, 70.2 Gy
(39.6 – 134.4 Gy)
median, 70 Gy
(48–70 Gy)
median 61.2 Gy (42–157 Gy).
Interval n/s 13 months
(range, 5–94 months)
26 months
(range, 2–318 months)
24 months (range, 3.1–252.6) 38 months
(range, 10–242 months)
53 months (range, 1–302 months)
Re-irradiation dose 5 (1 – 8) x 5 Gy
(3 – 16 Gy)
5 x 5 Gy 5 (2–5) x 6 3 x 10/13 Gy 5 x 6 Gy median dose of 40 Gy in 5 fractions
(interquartile range, 30–44 Gy)5 x 6.4 Gy Gy (4–12Gy) 5 x 5/8 Gy
5 x 7.2 Gy
5 x 8.0 Gy median 30 Gy (21–35 Gy)
5 x 8.8 Gy
Target size (median) TV 19.1 cm3
(range, 2.5 – 140.3 cm3)
TV 44.8 mm3
(range, 4.2–216.6 mm3)
Target volume 75 cm3
(range, 7–276 cm3)
GTV 22.6 cm3
(range, 0.2 to 114.9 cm3)
TV 63.4 cm3
(range 26.3–170.4 cm3)
TV 19,6ml (range, 4.5 – 103.9 ml)
Median follow-up time 19 months
(range 11–40 months)
n/s 16 months 17.3 months 24 months 10 months (range, 0–55 months)
Local control 26% @ 2 years n/s 30% @ 2 years * 61% @ 1 year 82% @ 2 years 77% @ 6 months
52.2% @ 2 years 59% @ 1 year
Overall survival 22% @ 2 years median 6 months
(95% CI 5–8 months)
12 months 52.1% @ 1 year cancer specific survival 76% @ 6 months
41% @ 2 years * 30.9% @ 2 years
64% @ 2 years 59% @ 1 year
Toxicity 1/22 grade 2, 3/25 grade 1 19/65 acute grade
1–3 toxicities
13/36 grade 3 acute toxicities 5/24 severe late side
effects (grade ≥ 3)
Acute/late grade 3 toxicity
was 15/6%, with
no grade 4–5 toxicity1/22 grade 3 mucositis 1/25 grade 2
No grade 3–5
toxicities
3/36 late toxicity: 1 bone
necrosis, 2 soft tissue
necrosisNo grade 4/5 toxicitiy
6/65 late grade 4 toxicities:
arterial bleeding, soft
tissue necrosis, fistula
formation
1 treatment related death
Abbreviations: BED10 = biologically effective dose (α/β of 10 for acute/tumor effects); n/s = not specified; @ = at time of; TV = tumor volume; GTV = gross tumor volume.
* definitively treated patients.
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nonsquamous cell cancers of the head and neck [60]. 34
patients were re-irradiated with a median SBRT dose of
40 Gy in 5 fractions. The toxicity and quality of life were
followed prospectively with a median follow-up of 10
months. The authors found promising local control rates
of 77% and 59% after 6 months and 12 months, respec-
tively. For tumors < 25 ml they reported a significant
improvement of local control compared to larger tumors
(> 25 ml). Acute and late grade 3 toxicities occurred in
15% and 6% of the patients respectively and no grade 4
or 5 toxicities were observed.
In conclusion, SBRT in the re-irradiation situation
for head and neck tumors is a promising salvage therapy
modality with encouraging local control rates and
justifiable toxicities. Severe late adverse events (grade
4–5 toxicities) have been reported in some studies
but are less frequent than in patients re-treated with
conventional techniques. Very high single fraction
doses of 10–13 Gy or higher should be avoided. Up
to now, no investigations have been performed for
comparison of SBRT and IMRT reirradiation. The
latter has been analyzed for reirradiation of head and
neck cancers over the last years showing encouraging
results as well.
SBRT re-irradiation for pelvic tumors
Primary treatment of pelvic cancers such as adenocar-
cinoma of the rectum, prostate cancer or gynaecological
tumors often includes radiotherapy. The locoregional re-
currence rate in women treated with radiochemotherapy
for cervical cancer is 35% over all stages [8] and 3% to
15% in patients treated for rectal adenocarcinoma [61].
Patients are frequently not considered eligible for salvage
surgery especially in the case of lateral pelvic wall in-
volvement or tumor abutment to the iliac vessels [62].
Dewas et al. presented a retrospective study of 16
patients reirradiated with Cyberknife for lateral pelvic
recurrences [63]. Patients were treated for recurrences
of primary anal canal cancer (6 patients), rectal cancer
(4 patients), uterine cervix cancer (4 patients), endomet-
rial cancer (1 patient) and bladder carcinoma (1 patient).
Patients had been treated before with a median RT dose
of 45 Gy (range, 20 Gy – 96 Gy), median interval be-
tween first RT course and retreatment was 5.1 months.
In the second course using SBRT, 36 Gy in 6 fractions
were delivered over three weeks. The median follow-up
was 10.6 months (1.9 to 20.5 months). The authors
reported a 1-year local control rate of 51.4%, median
disease-free survival of 8.3 months and actuarial one-
year survival of 46%. Adenocarcinoma showed a ten-
dency for better local control compared to sqamous cell
carcinoma (p = 0.09). Acute and late toxicities were
limited to grade ≤ 2.Guckenberger et al. [64] reported a series of 19
patients using SBRT for treatment of locally recurrent
cervical (n=12) or endometrial (n=7) cancer; three
patients were re-irradiated after adjuvant external beam
radiotherapy (n=1; conventionally fractionated 50 Gy) or
definitive external beam radiotherapy and brachytherapy
(n=2; conventionally fractionated 50–56 Gy; brachyther-
apy 3 × 8 Gy and 5 × 8.5 Gy) in the primary situation.
Patients were treated with 3 × 10 Gy (n=2) or 4 × 7 Gy
(n=1) with dose prescription to the 65% isodose. No
acute toxicity was observed but one patient developed
an ileus 6 months after SBRT. All patients were locally
controlled but follow-up was short ranging between 8
and 18 months. Two patients died 8 and 23 months after
SBRT.
In 2009 Deodato et al. published preliminary results of
SBRT in local and distant recurrences of gynaecological
tumors (RGT) [65]. The analyses included 11 patients trea-
ted with SBRT of whom 6 received SBRT as a reirradiation.
Previous RT doses ranged from 37.5 to 65 Gy (median 50.2
Gy). 8 patients had been pretreated with chemotherapy,
and 5 patients with surgery. Re-irradiation was performed
with 5 × 4 Gy, 5 × 5 y or 5 × 6 Gy on five consecu-
tive days on base of an institutional dose-escalation
protocol. PTV ranged from 4.0 cc to 273.0 cc (median,
42.0 cc). No patient showed acute toxicity or late toxicity
grade > 2. With a median follow-up of 19 months (range,
2–37 months) the authors reported a 2-year local
progression-free survival (LPFS) of 81.8% and a 2-year
metastases-free survival of 54.5%. In a subgroup analysis
the 2-year LPFS of patients treated with the highest
dose of 30 Gy was 87.5% and 66.7% for the remaining
population indicating better local control for the higher
treatment dose.
Recently, Jereczek-Fossa et al. reported on SBRT for
solitary recurrent primary, lymph node, or metastatic
prostate cancer [66]. 34 patients (38 lesions) were trea-
ted with SBRT using the robotic Cyberknife system: 15
patients were reirradiated for local recurrence, 4 patients
were reirradiated for anastomosis recurrence, 16 patients
were treated for single lymph node recurrence and 3
patients were treated for single metastasis. Median SBRT
dose was 30 Gy in 4.5 fractions and was performed as a
reirradiation in 27 of the 38 treated lesions, that is the
recurrent lesion was located in the previously irradiated
volume. 18 patients received androgen deprivation (me-
dian duration, 16.6 months) in addition to SBRT. The
median follow up was 16.9 months (range, 3 – 35.2
months). The mean interval between primary diagnosis
of prostate cancer and time of SBRT was 66 months
(24 – 180 months). 7 acute urinary events (18% of all
treatments) were reported (3 cases of grade 1, 2 cases
of grade 2, and 2 cases of grade 3 events). Grade 3
acute urinary events included macroscopic hematuria
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ing before SBRT due to prostatectomy. All but one
acute urinary event developed in patients with local/
anastomosis recurrence. Only one acute rectal grade 1
event occurred (3% of all patients). The authors observed
7 late urinary events (3 cases of grade 1, 2 cases of grade 2
and 2 cases of grade 3 events). Grade 3 late urinary events
included transient macroscopic hematuria and a per-
sistent worsening of urinary incontinence, that oc-
curred in the same patient who had an acute grade 3
event. These late urinary toxicities were observed in
patients treated for local recurrence to the prostate
region and patients treated for lymph node recur-
rences. Two late rectal events were reported (1 grade
1 and 1 grade 2, not otherwise specified). Biochemical
response was reported in 32 of 38 lesions. Considering
lesions treated with SBRT alone (no concomitant systemic
therapy), a complete PSA response was observed in
9 lesions (56.25%) and a partial PSA response in 4
lesions (25%). Disease progression was reported in
14 lesions after a median of 10 months (range, 2 – 17
months) but in-field progression occurred in only 3 lesions.
Time to progression was 11 months when androgen
deprivation was added to SBRT and 10 months with-
out. Progression-free survival rate was 42.6% at 30
months. With regard to these data SBRT as retreat-
ment for locally or regionally recurrent prostate cancer
seems to be practicable with good in-field tumor control
and a low toxicity rate. Further analyses are needed to
validate these findings and to identify patients with best
benefit of SBRT treatment.
Defoe et al. analyzed 14 patients treated with SBRT for
presacral recurrent adenocarcinoma of the rectum [67].
All patients had been previously irradiated with a median
of 50.4 Gy (range, 20 – 81 Gy). The treatment dose for
reirradiation was 36 Gy in 3 fractions for 11 patients and
3 patients were treated with a single fraction of 12, 16 or
18 Gy. Median tumor volume was 52.5 cc (range, 19 –
110 cc). Time of median follow-up was 16.5 months
(range, 6 – 69 months). The one- and two-year LC rates
were 90.9% and 68.2%, respectively. Overall survival was
90% after one year and 78.8% after two years. Neither
dose and fractionation nor tumor volume were significantly
correlated with LC and OS. No grade 3 or 4 genitourinary,
gastrointestinal, or neurologic toxicities occurred. One pa-
tient suffered from a recurrent pelvic abscess after SBRT,
with need for drainage. Seven patients (50%) reported pain
with recurrence before retreatment with SBRT and four of
these patients (57.1%) had no pain after SBRT without any
need for analgetic medication. SBRT in this small patient
cohort has been an efficient and well-tolerated treatment
for presacral recurrent rectal cancer.
In summary the role of SBRT in the reirradiation
of pelvic recurrences is currently poorly investigated.Recurrences from gynaecological tumors are most fre-
quently treated in palliative intention with chemotherapy
[68]. In case of lateral pelvic tumor recurrence, retreat-
ment with surgery is rarely possible due to pelvic wall or
iliac vessel involvement. Similarly, patients suffering
from presacral recurrence of rectal cancer often are not
amendable for curative resection, but even without treat-
ment do have a median survival of up to 8 months [69]. If
no treatment is offered or even if chemotherapy alone
without any local treatment is given, these patients de-
velop local complications particularly pain with dramatic
decrease of their quality of life [70]. SBRT therefore
might be a well-tolerated and short treatment to palliate
local symptoms and achieve improved local control. In
recurrent prostate cancer after primary treatment, an-
drogen deprivation is indicated for most patients. As
surgery is rarely performed in these patients due to
advanced age and tendency for systemic dissemination,
SBRT might be a feasible and safe treatment supplement
to systemic hormonal therapy.
Conclusion
Locoregional recurrences are a frequent challenge in on-
cology. Nevertheless, conventional radiotherapy for re-
irradiation has been performed in only few patients due
to the risk of normal tissue toxicity. SBRT may allow a
paradigm shift in this important clinical setting, where
alternative treatment options are limited.
The recurrent macroscopic tumor is precisely visua-
lized using modern multimodal imaging technologies
and the target volume is confined to gross tumor vol-
ume without inclusion of elective nodal regions or
volumes of potential microscopic tumor extension.
Safety margins are minimized by accurate, image-guided
treatment delivery and highly conformal treatment plan-
ning further reduces exposure of normal tissue. SBRT
combines these technologies and allows hypo-fractionated
dose escalation in these small target volumes. Shorter
treatment times of SBRT are a considerable advantage in
this clinical setting as re-treatment often takes place in a
palliative intention.
This small volume but intensified SBRT re-irradiation
has shown promising results with high rates of local
tumor and symptom control and simultaneously low
rates of severe normal tissue toxicity. Most mature
results have been described for SBRT re-irradiation of
vertebral metastases with high rates of pain and local
control; toxicity, especially radiation induced myelop-
athy, was low in all series. Re-irradiation in the head-
and-neck, thoracic and pelvic region has gained interest
with availability of SBRT and preliminary clinical results
are promising.
However, most if not all data available about SBRT re-
irradiation are based on small single institution studies
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terms of patient selection criteria, total irradiation dose,
fractionation, normal tissue dose constraints and target
volume concept varied substantially between studies. Pa-
tient selection bias and publication bias are additional
potential confounding factors. Consequently, prospective
studies are required for standardization of the promising
concept SBRT in the re-irradiation setting.
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